Studies biological age and frailty in people with chronic myeloid leukemia
Measures biological age and frailty in adults newly diagnosed with chronic myeloid leukemia.
Plain-language title generated from the registry record
Registry title: Value of Biological Age, in Addition to Individual Frailty, for Personalising the Management of Cancer Treated with Targeted Therapy
Key facts
- Where
- Annecy, Bordeaux, Caen, Clermont-Ferrand, Créteil, Grenoble, Le Puy-en-Velay, Lille, Limoges, Lyon, Marseille, Nancy, Paris, Rennes, Saint-Etienne, Toulouse, and Versailles, FranceSee the 17 sites
Where in France
- CHU Annecy-GenevoisAnnecy, FranceTaking people
- Institut BergonieBordeaux, FranceNot yet recruiting
- CHU CaenCaen, FranceTaking people
- CHU de Clermont-FerrandClermont-Ferrand, FranceTaking people
- Chu CreteilCréteil, FranceNot yet recruiting
- CHU Grenoble AlpesGrenoble, FranceNot yet recruiting
- Centre Hospitalier Emile RouxLe Puy-en-Velay, FranceTaking people
- CHRU LilleLille, FranceNot yet recruiting
- CHU LimogesLimoges, FranceTaking people
- Centre Leon BerardLyon, FranceNo longer taking part
- Institut Paoli-CalmettesMarseille, FranceTaking people
- CHU NancyNancy, FranceTaking people
- Groupe Hospitalier Paris Saclay - Site de BicêtreParis, FranceTaking people
- CHU RennesRennes, FranceTaking people
- CHU Saint-EtienneSaint-Etienne, FranceTaking people
- Institut Universitaire du Cancer de Toulouse - OncopoleToulouse, FranceTaking people
- CHU VersaillesVersailles, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital, Clermont-Ferrand
- Trial code
- NCT06130787
- Record updated
- 27 September 2024
- Original description
French prospective multicenter, open-label study involving newly diagnosed CML patients. Two assessments will be performed during the follow-up of these patients: individual frailty using geriatric tools and individual biological aging determined by DNA methylation analysis.Read full original descriptionShow less
Value of Biological Age, in Addition to Individual Frailty, for Personalising the Management of Cancer Treated with Targeted Therapy: the Model of Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors.
French prospective multicenter, open-label study involving newly diagnosed CML patients. Two assessments will be performed during the follow-up of these patients: individual frailty using geriatric tools and individual biological aging determined by DNA methylation analysis.
Inclusion: Age ≥18 years; CML in chronic phase at time of diagnosis. Diagnosis must be made no more than 3 months (90 days) prior to inclusion. Diagnosis of chronic-phase CML (European Leukemia Network [ELN] 2020 criteria; Baccarani et al 2013) with confirmation of a Philadelphia chromosome (Ph1). A cryptic Ph1 chromosome must be confirmed by FISH.Criteria must meet the definition of chronic phase CML; BCR ::ABL1 transcript quantifiable by quantitative PCR; 1st-line treatment with tyrosine kinase inhibitor; No tyrosine kinase inhibitor or hydroxyurea treatment received prior to first blood sampling (at diagnosis); Signature of informed consent for CML Observatory and signature of informed consent for BIO-TIMER protocol; Read and understand French; Enrolled in a social security plan or beneficiary of such a plan.
Exclusion: Treatment started prior to inclusion; CML in accelerated or blast phase; Refusal to participate in the study; Patients under guardianship, curatorship, deprivation of liberty or safeguard of justice; Pregnant or breast-feeding women.